×

TiGenix: TiGenix participates in key conferences in the first half of 2015

LEUVEN, Belgium, Feb. 2, 2015 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC's, in inflammatory and autoimmune diseases, announced today the conferences in which it is participating during the first half of 2015.

12-14 January
Biotech Showcase 2015, San Francisco, USA
Presenter: Eduardo Bravo, Chief Executive Officer

26-28 January
Phacilitate Cell and Gene Therapy Conference, Washington, USA
Presenter: Wilfried Dalemans, Chief Technical Officer

3 February
Biotech and Money London 2015, London, UK
Presenter: Eduardo Bravo, Chief Executive Officer

9-10 February
Bio CEO and Investor Conference, New York, USA
Presenter: Eduardo Bravo, Chief Executive Officer

18-21 February
ECCO Inflammatory Bowel Diseases Congress, Barcelona, Spain
Participants: Marie-Paule Richard, Chief Medical Officer; Maria Pascual, Vice President Regulatory Affairs and Corporate Quality; Mary Carmen Diez, Vice President Medical Affairs and New Product Commercialisation

9-11 March
Bio Europe Spring 2015, Paris, France
Participant: Claudia Jimenez, Senior Director Business Development

11 March
Petercam Belgium Investor Day, Milan, Italy
Participant: Claudia D'Augusta, Chief Financial Officer

12 March
EU Advanced Therapies Summit, Paris, France
Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality

17-20 March
International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium
Participant: Marie-Paule Richard, Chief Medical Officer

19 March
KBC Securities Institutional Healthcare Conference, Brussels, Belgium
Participants: Eduardo Bravo, Chief Executive Officer; Claudia D'Augusta, Chief Financial Officer

21 March
FlandersBio KBC Lifescience Retail Investor Event, Leuven, Belgium
Presenter: Wilfried Dalemans, Chief Technical Officer

25 March
ARM Annual Regenerative Medicine Investor Day, New York, USA
Presenter: Eduardo Bravo, Chief Executive Officer

26 March
Bio Capital Amsterdam, Amsterdam, Netherlands
Participant: Claudia D'Augusta, Chief Financial Officer

16 April
Kempen Healthcare and Life Sciences Conference, New York, USA
Participants: Eduardo Bravo, Chief Executive Officer; Claudia D'Augusta, Chief Financial Officer

22 April
Kempen Healthcare and Life Sciences Conference, Amsterdam, Netherlands
Participant: Claudia D'Augusta, Chief Financial Officer

25 April
FedInvest VFB Happening, Brussels, Belgium
Presenter: Eduardo Bravo, Chief Executive Officer

27-28 April
CF&B European Small Cap Event, Paris, France
Participant: Claudia D'Augusta, Chief Financial Officer

16-19 May
Digestive Disease Week, Washington, USA
Participant: Marie-Paule Richard, Chief Medical Officer

20-22 May
Annual World Stem Cell and Regenerative Medecine Congress, London, UK
Participants: Eduardo Bravo, Chief Executive Officer; Claudia Jimenez, Senior Director Business Development

21 May
Knowledge for Growth, Ghent, Belgium
Presenter: Wilfried Dalemans, Chief Technical Officer

2-3 June
PDA Europe Advanced Therapy Medicinal Products Conference, Amsterdam, Netherlands
Moderator: Wilfried Dalemans, Chief Technical Officer
Participant: Maria Pascual, Vice President Regulatory Affairs and Corporate Quality

10-13 June
EULAR Annual European Congress of Rheumatology, Rome, Italy
Participant: Marie-Paule Richard, Chief Medical Officer

15-18 June
Bio International Convention 2015, Philadelphia, USA
Participants: Eduardo Bravo, Chief Executive Officer; Claudia Jimenez, Senior Director Business Development

24-27 June
International Society for Stem Cell Research Annual Meeting, Stockholm, Sweden
Participant: Wilfried Dalemans, Chief Technical Officer

For more information:

Richard Simpson
Senior Consultant, Comfi sprl
T: +32 494 578 278
richard@comfi.be

About TiGenix

TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, or donor-derived, expanded adipose-derived stem cells, known as eASCs, in inflammatory and autoimmune diseases. Two products from this technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 is in Phase IIb for early rheumatoid arthritis, and in Phase Ib for severe sepsis. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect have been exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.

HUG#1890725

Source: TiGenix